NMS Capital has exited its investment in Flourish Research, a US-based clinical trial organization, through a sale to Genstar Capital. No financial terms were disclosed.

BioDuro-Sundia opens new kilogram laboratory at Shanghai to speed development from discovery to preclincal and clinical ...

Innovative products, such as those being developed by DELFI, will aid in the efficient progress of those medicines through the clinic," said Susan Macdonald, PhD, SVP Nonclinical Development & ...

For instance, AI algorithms can rapidly screen millions of compounds, significantly speeding up the initial phases of drug ..

Kochi: Amrita Hospital has commenced the third phase of testing for the 'Dengue All' vaccine, marking a significant milestone ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report ... based on EyePoint Pharmaceuticals’ notable advancements in their clinical trials and ...

The CRISP (Clinical Research Advancement Integrated Signature Program) will support advancing clinical research capabilities in the region, matching the mutual interests of the participating countries ...

biomodal, an omics-based life sciences technology and analytics company, today announced it will present new data highlighting the utility of duet mul ...

Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars ...

Chagas disease; rapid diagnostic test; diagnostic performance; cost-effectiveness; antiparasitic treatment Chagas disease (CD ...

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today ...